Skip to main content

Table 1 Clinical conditions between different types of fluid status before continuous renal replacement therapy

From: Fluid overload at start of continuous renal replacement therapy is associated with poorer clinical condition and outcome: a prospective observational study on the combined use of bioimpedance vector analysis and serum N-terminal pro-B-type natriuretic peptide measurement

Fluid status

Total

Type 1

Type 2

Type 3

Type 4

P value

Number (%)

89 (100)

19 (21.3)

15 (16.9)

10 (11.2)

45 (50.6)

 

Male/female

58/31

13/6

9/6

9/1

27/18

0.319

Age, years

49.0 ± 17.2

45.5 ± 15.1

44.7 ± 16.6

43.3 ± 17.9

53.1 ± 17.7

0.148

Height, cm

167.9 ± 10.4

168.5 ± 7.0

166.2 ± 8.8

176.9 ± 6.2

166.4 ± 12.0

0.015

Weight, kg

70.4 ± 15.8

69.0 ± 23.1

63.2 ± 10.0

78.5 ± 14.5

72.0 ± 12.7

0.023

Primary reason for hospitalization, n (%)

      

 Pancreatic

28 (31.4)

11 (57.9)

2 (13.3)

4 (40.0)

11 (24.4)

0.021

 Gastrointestinal

27 (30.3)

5 (26.3)

3 (20.0)

4 (40.0)

15 (33.3)

0.678

 Liver

4 (4.5)

2 (10.5)

1 (6.7)

0

1 (2.2)

0.431

 Pulmonary

9 (10.1)

0

3 (20.0)

1 (10.0)

5 (11.1)

0.289

 Trauma

8 (9.0)

0

1 (6.7)

1 (10.0)

6 (13.3)

0.393

 Other

13 (9.0)

1 (5.3)

5 (33.3)

0

7 (15.5)

0.066

Acute kidney injury, n (%)

60 (67.4)

7 (36.8)

9 (60.0)

6 (60.0)

38 (84.4)

0.002

Acute heart failure, n (%)

24 (27.0)

0

4 (26.7)

1 (10.0)

19 (42.2)

0.003

Severe sepsis, n (%)

63 (70.8)

10 (52.6)

8 (53.3)

9 (90.0)

36 (80.0)

0.032

Mechanical ventilation, n (%)

54 (60.7)

6 (31.6)

7 (46.7)

6 (60.0)

36 (80.0)

0.002

Comorbidities, n (%)

      

 Diabetes mellitus

11 (12.3)

2 (10.5)

3 (20.0)

0

6 (13.3)

0.514

 Chronic heart failure

4 (4.5)

0

2 (13.3)

0

2 (4.4)

0.256

 Chronic renal failure

7 (7.9)

0

6 (40.0)

0

1 (2.2)

<0.001

Urea, mmol/L

17.9 ± 12.7

13.6 ± 13.9

18.3 ± 12.6

16.3 ± 14.3

20.1 ± 11.8

0.301

Creatinine, μmol/L

287.5 ± 290.0

119.6 ± 138.3

496.7 ± 457.3

176.5 ± 191.0

313.2 ± 236.1

0.001

Oliguria, n (%)

45 (50.6%)

3 (15.8%)

11 (73.3%)

5 (50%)

26 (57.8%)

0.004

Urine output, mL/day

803 ± 796

1,309 ± 652

429 ± 388

916 ± 755

732 ± 878

0.008

Hemoglobin, g/L

103.5 ± 32.4

121.1 ± 34.2

109.9 ± 40.7

96.8 ± 16.0

95.5 ± 28.6

0.022

Platelet, ×109/L

136.0 ± 88.7

186.5 ± 70.2

165.7 ± 114.7

106.7 ± 75.7

111.2 ± 78.3

0.005

CRP, mg/L

133.4 ± 78.0

114.3 ± 70.4

105.4 ± 77.3

165.8 ± 73.2

141.7 ± 80.0

0.177

Albumin, g/L

30.3 ± 4.9

29.2 ± 5.1

32 ± 6.8

29.7 ± 3.5

30.3 ± 4.4

0.419

Bilirubin, mmol/La

27.6 (14.4-37.8)

23.3 (17.3-51.4)

10.0 (6.4-64.8)

45.5 (16.9-100.3)

27.6 (16.3-85.4)

0.304

Lactate, mmol/La

2.1 (1.3-3.8)

2.1 (1.5-3.4)

1.9 (1.3-3.8)

1.8 (1.3-3.5)

2.4 (1.3-3.9)

0.952

NT-ProBNP, pmol/La

274 (62-1,491)

15.4 (8.5-54)

591 (203-1,949)

61 (51-65)

817 (294-2,549)

<0.001

APACHE II score

18.8 ± 8.6

13.6 ± 6.7

17.1 ± 7.5

15.5 ± 8.4

22.2 ± 8.3

<0.001

SOFA score

11.7 ± 6.0

6.6 ± 3.0

10.6 ± 5.1

10.7 ± 6.4

14.6 ± 5.6

<0.001

SAPS II

41.7 ± 18.5

19.7 ± 12.7

42.5 ± 18.3

34.8 ± 22.2

48.4 ± 17.0

<0.001

Fluid balance at day 1, mLa

1,134 (169-2,301)

966 (210-1,702)

1,734 (602-3,092)

1,514 (670-2,157)

1,118 (−334-2,499)

0.557

Cumulative fluid balance over 3 days, mLa

2,729 (676-4,883)

2,729 (676-4,883)

3,843 (2,515-4,824)

2,517 (514-5,571)

2,611(−993-5,282)

0.7935

  1. aMedian (range). Fluid status: type 1, no overhydration and B-type natriuretic peptide (BNP) normal; type 2, no overhydration but BNP abnormal; type 3, overhydration but BNP normal; type 4, overhydration and BNP abnormal. APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP, C-reactive protein; NT-pro BNP, N-terminal pro-B-type natriuretic peptide; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment.